Ocular Therapeutix Insider Sell-to-Cover: 1,885 Shares Disposed
Rhea-AI Filing Summary
Ocular Therapeutix insider sale summary: Chief Strategy Officer Sanjay Nayak executed automatic sales of 1,885 shares of Ocular Therapeutix common stock on 08/25/2025 to satisfy tax withholding for restricted stock units that vested on 08/22/2025. The sales were made under a pre-established durable automatic sale instruction and were not discretionary. The weighted-average price reported for the sales is $12.04, with individual trade prices ranging from $11.89 to $12.1521. Following the reported disposals, the reporting person beneficially owned 279,738 shares.
Positive
- Transaction executed under a pre-established durable automatic sale instruction, indicating it was not a discretionary insider trade
- Detailed pricing disclosure provided: weighted-average sale price of $12.04 and explicit price range of $11.89 to $12.1521
- Form 4 reports post-transaction beneficial ownership of 279,738 shares, enabling transparency of insider holdings
Negative
- Reporting person disposed of shares (1,885 shares) which reduces insider ownership
- Limited context on materiality—the filing does not state the proportion of total outstanding shares or whether the holding is significant relative to total insider stake
Insights
TL;DR: Routine sell-to-cover for RSU tax withholding; not a discretionary trading decision and has limited informational value about company prospects.
The Form 4 discloses a narrow, administrative disposal of 1,885 shares by the Chief Strategy Officer under a pre-existing instruction to satisfy tax obligations on vested restricted stock units. The filing provides useful trade detail including a weighted-average price of $12.04 and the price range $11.89–$12.1521. Because the transaction is characterized as non-discretionary and tied to vesting, it typically does not signal a change in insider sentiment or corporate fundamentals. The post-transaction beneficial ownership of 279,738 shares is stated and may be referenced for monitoring insider holdings over time.
TL;DR: Disclosure aligns with required Section 16 reporting: sale made under a documented plan and properly reported by attorney-in-fact.
The disclosure indicates compliance with Section 16 reporting requirements and notes the sale occurred pursuant to a durable automatic sale instruction adopted February 21, 2024, which supports the affirmative defense under Rule 10b5-1(c). The form is signed by an attorney-in-fact, and the footnote offers the weighted-average pricing and price range detail that enhances transparency. The filing does not present governance concerns based on the information provided.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,885 | $12.04 | $23K |
Footnotes (1)
- Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2025. The sales do not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.89 to $12.1521, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
